Group B Streptococcus: or Streptococcus agalactiae is an encapsulated Gram-positive coccus capable of producing a
range of diseases in humans of all age ranges. In the neonate, the bacterium can cause severe life threatening sepsis and
meningitis (early and late onset disease) due to ascending spread of GBS from the birth canal of colonized females (~30% of
total) who are typically asymptomatic.
Using currently available information regarding the expected profile, predicted target groups for a GBS vaccine VacZine Analytics has modelled theoretical vaccine demand in the major Western markets.
The provided model and presentation also give indications of potential revenue (for vaccine
manufacturers) using adjustable inputs of vaccine pricing, penetration and number of doses per course.
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 15.0%.
Please review the TERMS and CONDITIONS of purchase.
